DK305884A
(da)
*
|
1983-06-24 |
1984-12-25 |
Yamanouchi Pharma Co Ltd |
Phenoxyderivat, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
|
CN1003445B
(zh)
*
|
1984-10-03 |
1989-03-01 |
武田药品工业株式会社 |
噻唑烷二酮衍生物,其制备方法和用途
|
US4812570A
(en)
*
|
1986-07-24 |
1989-03-14 |
Takeda Chemical Industries, Ltd. |
Method for producing thiazolidinedione derivatives
|
FI91869C
(fi)
*
|
1987-03-18 |
1994-08-25 |
Tanabe Seiyaku Co |
Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
|
US4968707A
(en)
*
|
1987-06-10 |
1990-11-06 |
Pfizer Inc. |
Oxazolidin-2-one derivatives as hypoglycemic agents
|
GB8713861D0
(en)
*
|
1987-06-13 |
1987-07-15 |
Beecham Group Plc |
Compounds
|
EP0295828A1
(de)
*
|
1987-06-13 |
1988-12-21 |
Beecham Group Plc |
Chemische Verbindungen
|
US4798835A
(en)
*
|
1987-12-02 |
1989-01-17 |
Pfizer Inc. |
dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
|
US4791125A
(en)
*
|
1987-12-02 |
1988-12-13 |
Pfizer Inc. |
Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
|
GB8820389D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Beecham Group Plc |
Novel compounds
|
GB8919417D0
(en)
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
US4997948A
(en)
*
|
1989-10-27 |
1991-03-05 |
American Home Products |
5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
|
US5356913A
(en)
*
|
1990-02-09 |
1994-10-18 |
The Upjohn Company |
Use of insulin sensitizing agents to treat hypertension
|
ES2059121T5
(es)
†
|
1990-02-09 |
2000-12-01 |
Upjohn Co |
Uso de agentes sensibilizantes de la insulina para tratar la hipertension.
|
EP0839812A1
(de)
*
|
1990-04-27 |
1998-05-06 |
Sankyo Company Limited |
Herstellung von Benzylthiazolidinederivaten
|
GB9023584D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
US5158966A
(en)
*
|
1991-02-22 |
1992-10-27 |
The University Of Colorado Foundation, Inc. |
Method of treating type i diabetes
|
US5183823A
(en)
*
|
1991-04-11 |
1993-02-02 |
Takeda Chemical Industries, Ltd. |
Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
|
US5441971A
(en)
*
|
1991-04-11 |
1995-08-15 |
The Upjohn Company |
Thiazolidinedione derivatives, production and use thereof
|
ES2161692T3
(es)
*
|
1991-04-11 |
2001-12-16 |
Upjohn Co |
Derivados de tiazolidindiona, produccion y uso de los mismos.
|
FR2680512B1
(fr)
*
|
1991-08-20 |
1995-01-20 |
Adir |
Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
|
GB9124513D0
(en)
*
|
1991-11-19 |
1992-01-08 |
Smithkline Beecham Plc |
Novel process
|
US5741803A
(en)
*
|
1992-09-05 |
1998-04-21 |
Smithkline Beecham Plc |
Substituted thiazolidinedionle derivatives
|
GB9218830D0
(en)
*
|
1992-09-05 |
1992-10-21 |
Smithkline Beecham Plc |
Novel compounds
|
IL106877A
(en)
*
|
1992-09-10 |
1998-03-10 |
Lilly Co Eli |
Rodinin derivatives for use as drugs for the treatment of Alzheimer's disease
|
US5594016A
(en)
*
|
1992-12-28 |
1997-01-14 |
Mitsubishi Chemical Corporation |
Naphthalene derivatives
|
JP2845743B2
(ja)
*
|
1992-12-28 |
1999-01-13 |
三菱化学株式会社 |
新規なナフタレン誘導体
|
USRE39384E1
(en)
|
1993-09-01 |
2006-11-07 |
Smithkline Beecham P.L.C. |
Substituted thiazolidinedione derivatives
|
US6046222A
(en)
*
|
1993-09-15 |
2000-04-04 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US5478852C1
(en)
*
|
1993-09-15 |
2001-03-13 |
Sankyo Co |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
|
US5874454A
(en)
*
|
1993-09-15 |
1999-02-23 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
NZ274346A
(en)
*
|
1993-09-15 |
1997-06-24 |
Sankyo Co |
Use of various thiazolidine-2,4-dione and oxazolidine-2,4-dione derivatives to prevent or delay onset of non-insulin dependent diabetes mellitus
|
NZ282143A
(en)
*
|
1994-03-08 |
1997-12-19 |
American Home Prod |
5-[3-arylprop-2-ynyl]-5-(aryl-sulphonyl (or -sulphanyl))thiazolidine-2,4-diones and corresponding sulphonyl derivatives; medicaments
|
US6251928B1
(en)
*
|
1994-03-16 |
2001-06-26 |
Eli Lilly And Company |
Treatment of alzheimer's disease employing inhibitors of cathepsin D
|
RU2137770C1
(ru)
*
|
1994-10-20 |
1999-09-20 |
Ниппон Кемифар Ко., Лтд. |
Производные хинолина
|
US5708012A
(en)
*
|
1995-04-28 |
1998-01-13 |
Sankyo Company, Limited |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
|
AU5121796A
(en)
*
|
1995-05-08 |
1996-11-29 |
Nippon Chemiphar Co. Ltd. |
2,4-thiazolidinedione or oxazolidinedione derivatives and hy poglycemic agent
|
TWI238064B
(en)
|
1995-06-20 |
2005-08-21 |
Takeda Chemical Industries Ltd |
A pharmaceutical composition for prophylaxis and treatment of diabetes
|
IL118778A
(en)
*
|
1995-07-03 |
1999-07-14 |
Sankyo Co |
Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
|
EP0783888A1
(de)
*
|
1995-12-26 |
1997-07-16 |
Sankyo Company Limited |
Verwendung von Troglitazone und verwandten Thiazolidinedionen zur Herstellung eines Medikaments für die Behandlung und Vorbeugung der Osteoporose
|
IL120443A
(en)
*
|
1996-03-18 |
2000-07-16 |
Sankyo Co |
Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
|
US5958957A
(en)
*
|
1996-04-19 |
1999-09-28 |
Novo Nordisk A/S |
Modulators of molecules with phosphotyrosine recognition units
|
AU2381397A
(en)
*
|
1996-04-19 |
1997-11-12 |
Novo Nordisk A/S |
Modulators of molecules with phosphotyrosine recognition units
|
CA2257284C
(en)
*
|
1996-05-31 |
2005-10-04 |
Sankyo Company Limited |
Remedy for autoimmune diseases
|
US5952509A
(en)
*
|
1996-06-27 |
1999-09-14 |
Takeda Chemical Industries, Ltd. |
Production of benzaldehyde compounds
|
WO1998020871A1
(fr)
*
|
1996-11-08 |
1998-05-22 |
Nippon Chemiphar Co., Ltd. |
Agent diminuant la graisse viscerale
|
WO1998039967A1
(en)
*
|
1997-03-12 |
1998-09-17 |
The General Hospital Corporation |
A method for treating or preventing alzheimer's disease
|
US5908859A
(en)
*
|
1997-08-11 |
1999-06-01 |
Eli Lilly And Company |
Benzothiophenes for inhibiting hyperlipidemia
|
HUP9902721A2
(hu)
|
1997-11-25 |
1999-12-28 |
The Procter & Gamble Co. |
Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
|
WO1999030739A1
(fr)
*
|
1997-12-16 |
1999-06-24 |
Sankyo Company, Limited |
Remede contre la leucemie
|
GB9726568D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US20040058873A1
(en)
*
|
1998-03-12 |
2004-03-25 |
Esmond Robert W. |
Method for treating or preventing Alzheimer's disease
|
WO2000030628A2
(en)
*
|
1998-11-20 |
2000-06-02 |
Genentech, Inc. |
Method of inhibiting angiogenesis
|
US6191154B1
(en)
|
1998-11-27 |
2001-02-20 |
Case Western Reserve University |
Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
|
TWI249401B
(en)
*
|
1999-04-14 |
2006-02-21 |
Takeda Chemical Industries Ltd |
Agent for improving ketosis
|
ATE365158T1
(de)
|
1999-04-28 |
2007-07-15 |
Inst Med Molecular Design Inc |
Pyrimidincarbonsäurederivate
|
EP1109796A1
(de)
*
|
1999-07-01 |
2001-06-27 |
Geron Corporation |
Telomerase inhibitoren und verfahren zu ihren verwendungen
|
JP2001072592A
(ja)
|
1999-07-01 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
テロメラーゼ阻害剤
|
US7390824B1
(en)
*
|
1999-09-07 |
2008-06-24 |
Bristol-Myers Squibb Company |
Method for treating diabetes employing an aP2 inhibitor and combination
|
AR028299A1
(es)
|
1999-09-17 |
2003-05-07 |
Novartis Ag |
Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
|
US6878749B2
(en)
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
ES2156574B1
(es)
*
|
1999-11-18 |
2002-02-01 |
Vita Invest Sa |
Nuevos derivados de tiazolidindiona como agentes antidiabeticos
|
CN1215059C
(zh)
|
1999-12-03 |
2005-08-17 |
京都药品工业株式会社 |
新的杂环化合物及其盐和它们的医药用途
|
DE122008000018I1
(de)
|
2000-01-21 |
2008-08-14 |
Novartis Pharma Ag |
Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
|
US6958355B2
(en)
*
|
2000-04-24 |
2005-10-25 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6680387B2
(en)
*
|
2000-04-24 |
2004-01-20 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
AU4882801A
(en)
*
|
2000-04-25 |
2001-11-07 |
Kyorin Pharmaceutical Co. Ltd. |
Novel stable crystal of thiazolidinedione derivative and process for producing the same
|
AU2001294673A1
(en)
|
2000-09-21 |
2002-04-02 |
Aryx Therapeutics |
Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
US6452014B1
(en)
|
2000-12-22 |
2002-09-17 |
Geron Corporation |
Telomerase inhibitors and methods of their use
|
ATE341343T1
(de)
*
|
2000-12-26 |
2006-10-15 |
Sankyo Co |
Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
|
SK9502003A3
(en)
*
|
2001-01-26 |
2003-12-02 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
MXPA03006724A
(es)
*
|
2001-01-26 |
2003-10-24 |
Schering Corp |
Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares.
|
RU2756946C2
(ru)
*
|
2001-01-26 |
2021-10-07 |
Мерк Шарп И Доум Корп. |
Применение замещенных азетидинонов для лечения ситостеролемии
|
US20030053981A1
(en)
*
|
2001-01-26 |
2003-03-20 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
ATE348649T1
(de)
*
|
2001-01-26 |
2007-01-15 |
Schering Corp |
Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
EP1671650A1
(de)
*
|
2001-01-26 |
2006-06-21 |
Schering Corporation |
Kombinationen von einem Hemmer der Sterol-Absorption und Nicotinsäure zur Behandlung von kardiovaskulären Indikationen
|
KR100926247B1
(ko)
*
|
2001-02-24 |
2009-11-12 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
|
KR200249057Y1
(ko)
*
|
2001-03-22 |
2001-10-19 |
김진환 |
뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
|
CN100577175C
(zh)
*
|
2001-04-04 |
2010-01-06 |
奥索-麦克尼尔药品公司 |
包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
|
US20060047000A1
(en)
*
|
2001-04-24 |
2006-03-02 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
WO2002087580A1
(fr)
*
|
2001-04-25 |
2002-11-07 |
Takeda Chemical Industries, Ltd. |
Promoteurs d'expression d'abc
|
WO2002088120A1
(en)
*
|
2001-04-26 |
2002-11-07 |
Léciva, a.s. |
Method for obtaining pioglitazone as an antidiabetic agent
|
CN1242994C
(zh)
*
|
2001-05-29 |
2006-02-22 |
京都药品工业株式会社 |
杂环化合物及其医疗用途
|
WO2002096904A1
(fr)
*
|
2001-05-29 |
2002-12-05 |
Kyoto Pharmaceutical Industries, Ltd. |
Nouveaux derives heterocycliques et utilisation medicale de ces derives
|
WO2003013609A1
(en)
*
|
2001-08-03 |
2003-02-20 |
Takeda Chemical Industries, Ltd. |
Sustained-release medicines
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
BR0212907A
(pt)
*
|
2001-09-21 |
2004-10-13 |
Schering Corp |
Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
|
JP2005504091A
(ja)
*
|
2001-09-21 |
2005-02-10 |
シェーリング コーポレイション |
ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
US7135485B2
(en)
*
|
2001-09-28 |
2006-11-14 |
Teva Pharmaceutical Industries Ltd. |
Pioglitazone hydrochloride
|
US20050101638A1
(en)
*
|
2002-11-08 |
2005-05-12 |
Webb Randy L. |
Combination of organic compounds
|
EP1465881A4
(de)
*
|
2001-12-20 |
2005-04-13 |
Teva Pharma |
Hydrierung von vorstufen zu thiazolidindion-antihyperglykämika
|
US20050187258A1
(en)
*
|
2001-12-20 |
2005-08-25 |
Ben-Zion Dolitzky |
Hydrogenation of precursors to thiazolidinedione antihyperglycemics
|
ITRM20020016A1
(it)
*
|
2002-01-15 |
2003-07-15 |
Sigma Tau Ind Farmaceuti |
Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
|
US20050084840A1
(en)
*
|
2002-01-23 |
2005-04-21 |
Hideki Endoh |
Method for screening drug for improving insulin resistance
|
US7015345B2
(en)
*
|
2002-02-21 |
2006-03-21 |
Asahi Kasei Pharma Corporation |
Propionic acid derivatives
|
KR100450700B1
(ko)
*
|
2002-03-22 |
2004-10-01 |
주식회사종근당 |
티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
|
US20050119314A1
(en)
*
|
2002-04-05 |
2005-06-02 |
Sankyo Company, Limited |
Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
|
US8911781B2
(en)
|
2002-06-17 |
2014-12-16 |
Inventia Healthcare Private Limited |
Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
|
US8993773B2
(en)
|
2002-07-16 |
2015-03-31 |
Cadila Healthcare Limited |
Process to prepare pioglitazone via several novel intermediates
|
EP1521753B1
(de)
|
2002-07-16 |
2007-09-05 |
Cadila Healthcare Ltd. |
Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
|
US7407955B2
(en)
*
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
AU2003260813A1
(en)
*
|
2002-09-12 |
2004-04-30 |
Themis Laboratories Private Limited |
Improved process for preparation of thiazolidinedione derivatives
|
US8084058B2
(en)
|
2002-09-20 |
2011-12-27 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US9060941B2
(en)
*
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7785627B2
(en)
*
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7959946B2
(en)
*
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
KR20050053677A
(ko)
|
2002-09-20 |
2005-06-08 |
안드렉스 랩스 엘엘씨 |
비구아나이드와 티아졸리디네디온 유도체를 함유한 약제학적 투여형태
|
US20040092499A1
(en)
*
|
2002-11-06 |
2004-05-13 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of autoimmune disorders
|
EP1601668B1
(de)
|
2003-03-07 |
2008-08-27 |
Schering Corporation |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
ES2318274T3
(es)
|
2003-03-07 |
2009-05-01 |
Schering Corporation |
Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
JP2006519869A
(ja)
|
2003-03-07 |
2006-08-31 |
シェーリング コーポレイション |
置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
|
WO2004087053A2
(en)
|
2003-03-25 |
2004-10-14 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
WO2004108721A1
(en)
*
|
2003-04-01 |
2004-12-16 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl] methyl]-2,4-thiazolidinedione
|
ES2219180B1
(es)
*
|
2003-05-09 |
2006-03-01 |
Medichem, S.A. |
Compuesto intermedio util para la preparacion de pioglitazona.
|
JP2007502847A
(ja)
*
|
2003-05-13 |
2007-02-15 |
シントン・ベスローテン・フェンノートシャップ |
チアゾリジンジオン誘導体およびその化合物を製造する方法
|
SI1622899T1
(sl)
*
|
2003-05-13 |
2007-10-31 |
Synthon Bv |
Pioglitazonsulfat, farmacevtski sestavki in njihova uporaba
|
US7230016B2
(en)
|
2003-05-13 |
2007-06-12 |
Synthon Ip Inc. |
Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
|
US20050004179A1
(en)
*
|
2003-05-22 |
2005-01-06 |
Pedersen Ward A. |
Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
|
JPWO2004106542A1
(ja)
*
|
2003-05-29 |
2006-07-20 |
三共株式会社 |
インスリン抵抗性改善剤及びそのスクリーニング方法
|
US7923467B2
(en)
|
2003-05-30 |
2011-04-12 |
Ranbaxy Laboratories, Inc. |
Substituted pyrrole derivatives and their use as HMG-CO inhibitors
|
EP1506967B1
(de)
|
2003-08-13 |
2007-11-21 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl Peptidase Inhibitoren.
|
WO2005021542A2
(en)
*
|
2003-08-28 |
2005-03-10 |
Ranbaxy Laboratories Limited |
Process for the preparation of pioglitazone
|
WO2005021543A1
(en)
*
|
2003-09-03 |
2005-03-10 |
Biocon Limited |
Phosphoric acid salt of 5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione
|
JP2007505121A
(ja)
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
JP5140881B2
(ja)
*
|
2003-09-17 |
2013-02-13 |
要 川杉 |
医薬組成物
|
US20050096307A1
(en)
*
|
2003-11-05 |
2005-05-05 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
WO2005080387A2
(en)
*
|
2004-02-20 |
2005-09-01 |
Synthon B.V. |
Processes for making pioglitazone and compounds of the processes
|
WO2005095381A1
(en)
*
|
2004-03-15 |
2005-10-13 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CN1972715A
(zh)
*
|
2004-03-29 |
2007-05-30 |
三共株式会社 |
含有胰岛素抵抗改善剂的糖尿病治疗剂
|
US7161756B2
(en)
*
|
2004-05-10 |
2007-01-09 |
Tandberg Data Storage Asa |
Method and system for communication between a tape drive and an external device
|
US20060025478A1
(en)
*
|
2004-07-27 |
2006-02-02 |
Keisuke Inoue |
Medicine for prevention or treatment of diabetes
|
TW200608967A
(en)
*
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
US20070259927A1
(en)
*
|
2004-08-26 |
2007-11-08 |
Takeda Pharmaceutical Company Limited |
Remedy for Diabetes
|
WO2006035459A1
(en)
*
|
2004-09-28 |
2006-04-06 |
Morepen Laboratories Limited |
An improved process for the production of derivatives of thiozolidinediones and their precursors
|
US20060089387A1
(en)
*
|
2004-10-26 |
2006-04-27 |
Le Huang |
Stabilized pharmaceutical composition comprising antidiabetic agent
|
DE102004054054A1
(de)
*
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
EP2805953B1
(de)
|
2004-12-21 |
2016-03-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl-Peptidase-Hemmer
|
JP5091106B2
(ja)
*
|
2005-03-08 |
2012-12-05 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
真性糖尿病の治療のためのロフルミラスト
|
US20070269486A1
(en)
*
|
2005-03-14 |
2007-11-22 |
Conor Medsystems, Llc. |
Methods and Devices for Reducing Tissue Damage After Ischemic Injury
|
KR20080025662A
(ko)
*
|
2005-03-18 |
2008-03-21 |
오키드 케미칼즈 앤드 파마수티컬즈 리미티드 |
신규 티로신 유도체
|
WO2006117654A1
(en)
*
|
2005-05-03 |
2006-11-09 |
Ranbaxy Laboratories Limited |
Processes for the preparation of pioglitazone or salts thereof
|
KR20080028415A
(ko)
*
|
2005-07-12 |
2008-03-31 |
다이이찌 산쿄 가부시키가이샤 |
PPARγ 애고니스트를 함유하는 의약 조성물
|
WO2007029062A2
(en)
*
|
2005-07-29 |
2007-03-15 |
Orchid Research Laboratories Limited |
Novel pyridine derivatives
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
EP1942898B2
(de)
*
|
2005-09-14 |
2014-05-14 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
|
EP1924567B1
(de)
|
2005-09-16 |
2012-08-22 |
Takeda Pharmaceutical Company Limited |
Verfahren zur herstellung von pyrimidindionderivaten
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
KR101329112B1
(ko)
|
2005-11-08 |
2013-11-14 |
랜박시 래보러터리스 리미티드 |
(3r,5r)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
|
TW200730173A
(en)
*
|
2005-12-16 |
2007-08-16 |
Sankyo Co |
Pharmaceutical composition enhancing production of adiponectin
|
MX2008011870A
(es)
*
|
2006-03-16 |
2009-02-10 |
Metabolic Solutions Dev Compan |
Terapias de combinacion de analogos de tiazolidindiona y agonistas glucocorticoides.
|
UA96441C2
(ru)
*
|
2006-03-16 |
2011-11-10 |
Метаболик Солюшнз Девелопмент Компани |
Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
|
ES2388555T3
(es)
*
|
2006-03-16 |
2012-10-16 |
Metabolic Solutions Development Company Llc |
Análogos de tiazolidindiona
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
PE20080251A1
(es)
*
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
CN103951667A
(zh)
|
2006-05-04 |
2014-07-30 |
勃林格殷格翰国际有限公司 |
多晶型
|
EP2037928B1
(de)
|
2006-06-26 |
2012-01-11 |
Amgen Inc. |
Verfahren zur behandlung von atherosklerose
|
KR100791399B1
(ko)
|
2006-09-06 |
2008-01-07 |
동우신테크 주식회사 |
염산 피오글리타존의 제조방법
|
JP2010502670A
(ja)
|
2006-09-07 |
2010-01-28 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
真性糖尿病のための組合せ治療
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
US20080182880A1
(en)
*
|
2006-09-28 |
2008-07-31 |
Mailatur Sivaraman Mohan |
Pioglitazone composition
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
CA2670730A1
(en)
*
|
2006-12-13 |
2008-06-26 |
Gilead Sciences, Inc. |
Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
|
WO2008075380A2
(en)
*
|
2006-12-21 |
2008-06-26 |
Ind-Swift Laboratories Limited |
Process for the preparation of thiazolidine derivatives
|
EP2016076A2
(de)
*
|
2007-01-22 |
2009-01-21 |
Teva Pharmaceutical Industries Ltd. |
Polymorphe formen von rosiglitazon-hydrobromid und herstellungsverfahren dafür
|
DK2107905T3
(da)
*
|
2007-02-01 |
2011-01-31 |
Takeda Pharmaceutical |
Fast sammensætning omfattende alogliptin og pioglitazon
|
KR101126383B1
(ko)
|
2007-02-07 |
2012-04-12 |
교와 핫꼬 기린 가부시키가이샤 |
3환계 화합물
|
WO2008105326A1
(ja)
*
|
2007-02-28 |
2008-09-04 |
Ohara Chemical Industries, Ltd. |
2-イミノ-4-チアゾリジノン誘導体及び2,4-チアゾリジンジオン誘導体の製造方法
|
TW200901959A
(en)
|
2007-03-09 |
2009-01-16 |
Indigene Pharmaceuticals Inc |
Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
|
US8093236B2
(en)
*
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
ES2385114T3
(es)
|
2007-03-30 |
2012-07-18 |
Ambrx, Inc. |
Polipéptidos de FGF-21 modificados y sus usos
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
US20160331729A9
(en)
*
|
2007-04-11 |
2016-11-17 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US11241420B2
(en)
|
2007-04-11 |
2022-02-08 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
BRPI0810525B8
(pt)
|
2007-04-11 |
2021-05-25 |
Omeros Corp |
uso de pioglitazona ou rosiglitazona pra tratar a dependência em álcool, cocaína e nicotina, composições farmacêuticas e formas de dosagem, e combinações farmacêuticas contendo pioglitazona ou rosiglitazona
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EA021544B1
(ru)
|
2007-06-04 |
2015-07-30 |
Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити |
Триарильные соединения и фармацевтические композиции, их содержащие
|
CN103601792B
(zh)
|
2007-06-04 |
2016-06-29 |
协同医药品公司 |
有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
|
EP2489730B1
(de)
|
2007-07-26 |
2015-12-30 |
Amgen, Inc |
Modifizierte Lecithin-Cholesterin-Acyltransferase-Enzyme
|
NZ600126A
(en)
*
|
2007-08-17 |
2013-12-20 |
Boehringer Ingelheim Int |
Purine derivatives for use in the treatment of fap-related diseases
|
WO2009035997A2
(en)
*
|
2007-09-14 |
2009-03-19 |
Cara Therapeutics, Inc. |
Benzo-fused heterocycles
|
AU2008301905B2
(en)
|
2007-09-14 |
2013-06-27 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogues for the treatment of hypertension
|
US8304441B2
(en)
|
2007-09-14 |
2012-11-06 |
Metabolic Solutions Development Company, Llc |
Thiazolidinedione analogues for the treatment of metabolic diseases
|
US8722710B2
(en)
|
2007-09-26 |
2014-05-13 |
Deuterx, Llc |
Deuterium-enriched pioglitazone
|
US20090118514A1
(en)
*
|
2007-11-06 |
2009-05-07 |
Raghupathi Reddy Anumula |
Processes for preparing pioglitazone and its pharmaceutically acceptable salts
|
JP5334422B2
(ja)
*
|
2008-02-13 |
2013-11-06 |
株式会社トクヤマ |
5−{4−[2−(5−エチル−2−ピリジル)エトキシ]ベンジル}−2−イミノ−4−チアゾリジノンの製造方法
|
JP5197063B2
(ja)
*
|
2008-02-21 |
2013-05-15 |
株式会社トクヤマ |
2−ブロモ−3−{4−[2−(5−エチル−2−ピリジル)エトキシ]フェニル}プロピオン酸メチルの製造方法
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
WO2009133576A1
(en)
*
|
2008-04-28 |
2009-11-05 |
Erregierre S.P.A. |
A process for the preparation of 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene and pioglitazone
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP3241839B1
(de)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
|
US8486980B2
(en)
|
2008-08-06 |
2013-07-16 |
Kyowa Hakko Kirin Co., Ltd. |
Tricyclic compound
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
EP2789695B1
(de)
|
2008-08-12 |
2019-10-30 |
Zinfandel Pharmaceuticals, Inc. |
Anti-Alzheimer-Behandlung von Probanden, die durch Nachweis einer genetischen Variante im TOMM40-Gen bei rs 10524523 identifiziert wurden
|
US8846315B2
(en)
|
2008-08-12 |
2014-09-30 |
Zinfandel Pharmaceuticals, Inc. |
Disease risk factors and methods of use
|
MX2011001525A
(es)
*
|
2008-08-15 |
2011-03-29 |
Boehringer Ingelheim Int |
Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
|
CN102112444A
(zh)
*
|
2008-09-02 |
2011-06-29 |
株式会社德山 |
脱溴化氢化抑制剂
|
BRPI0919288A2
(pt)
|
2008-09-10 |
2015-12-15 |
Boehring Ingelheim Internat Gmbh |
teriapia de combinação para tratamento de diabetes e condições relacionadas.
|
WO2010041538A1
(ja)
*
|
2008-10-10 |
2010-04-15 |
株式会社トクヤマ |
カルボニルオキシ化合物の製造方法
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JP5473303B2
(ja)
*
|
2008-12-01 |
2014-04-16 |
株式会社トクヤマ |
2−ブロモ−3−{4−[2−(5−エチル−2−ピリジル)エトキシ]フェニル}プロピオン酸メチルの製造方法
|
US20100144140A1
(en)
*
|
2008-12-10 |
2010-06-10 |
Novellus Systems, Inc. |
Methods for depositing tungsten films having low resistivity for gapfill applications
|
MX2011006713A
(es)
|
2008-12-23 |
2011-07-13 |
Boehringer Ingelheim Int |
Formas salinas de compuesto organico.
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
KR20110110766A
(ko)
*
|
2009-01-20 |
2011-10-07 |
가부시끼가이샤 도꾸야마 |
2-브로모-3-{4-[2-(5-에틸-2-피리딜)에톡시]페닐}프로피온산메틸의 탈브롬화 수소화를 억제하는 방법
|
JP2010208957A
(ja)
*
|
2009-03-06 |
2010-09-24 |
Tokuyama Corp |
結晶構造を有する5−{4−[2−(5−エチル−2−ピリジル)エトキシ]ベンジル}−2−イミノ−4−チアゾリジノン及びその製造方法
|
CN102348457A
(zh)
|
2009-03-11 |
2012-02-08 |
奥默罗斯公司 |
预防和治疗成瘾的组合物和方法
|
US8686009B2
(en)
|
2009-06-25 |
2014-04-01 |
Alkermes Pharma Ireland Limited |
Prodrugs of NH-acidic compounds
|
PT2445502T
(pt)
|
2009-06-25 |
2017-09-22 |
Alkermes Pharma Ireland Ltd |
Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
|
US20110065756A1
(en)
*
|
2009-09-17 |
2011-03-17 |
De Taeye Bart M |
Methods and compositions for treatment of obesity-related diseases
|
JP5697260B2
(ja)
|
2009-11-13 |
2015-04-08 |
東レ株式会社 |
糖尿病の治療または予防薬
|
KR20230021159A
(ko)
|
2009-11-27 |
2023-02-13 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
RU2564661C2
(ru)
*
|
2009-12-15 |
2015-10-10 |
МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи |
Соли тиазолидиндиона со сниженным сродством к ppar для лечения нарушений обмена веществ
|
WO2011091134A2
(en)
|
2010-01-22 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
|
JP2013523681A
(ja)
|
2010-03-30 |
2013-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Sglt2インヒビター及びppar−ガンマアゴニストを含む医薬組成物並びにその使用
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
WO2011161161A1
(en)
|
2010-06-24 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
Diabetes therapy
|
WO2012028934A1
(en)
|
2010-09-01 |
2012-03-08 |
Lupin Limited |
Pharmaceutical composition comprising metformin and pioglitazone
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
US9102666B2
(en)
|
2011-01-10 |
2015-08-11 |
Zinfandel Pharmaceuticals, Inc. |
Methods and drug products for treating Alzheimer's disease
|
WO2012153312A1
(en)
|
2011-05-11 |
2012-11-15 |
Ranbaxy Laboratories Limited |
Process for the purification of pioglitazone
|
HUE043540T2
(hu)
|
2011-07-15 |
2019-08-28 |
Boehringer Ingelheim Int |
Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
|
JP6086865B2
(ja)
|
2011-08-03 |
2017-03-01 |
協和発酵キリン株式会社 |
ジベンゾオキセピン誘導体
|
WO2013068486A1
(en)
|
2011-11-08 |
2013-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of male infertility
|
EP2788384B1
(de)
|
2011-12-08 |
2017-08-09 |
Amgen Inc. |
Agonistische menschliche lcat-antigenbindende proteine und ihre verwendung in der therapie
|
AU2012351747B2
(en)
|
2011-12-15 |
2016-05-12 |
Alkermes Pharma Ireland Limited |
Prodrugs of secondary amine compounds
|
US20130158077A1
(en)
|
2011-12-19 |
2013-06-20 |
Ares Trading S.A. |
Pharmaceutical compositions
|
US9504679B2
(en)
|
2011-12-19 |
2016-11-29 |
Bjoern Colin Kahrs |
Pharmaceutical compositions comprising glitazones and Nrf2 activators
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2638898A1
(de)
|
2012-03-16 |
2013-09-18 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Metformin- und Pioglitazonformulierung mit verschiedenen Freisetzungsprofilen
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
CA2890086C
(en)
|
2012-11-05 |
2022-05-31 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) |
Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist preferably a thiazolid nedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
|
JP6800013B2
(ja)
|
2013-03-14 |
2020-12-16 |
ポクセル・ソシエテ・アノニムPoxel SA |
重水素化2,4−チアゾリジンジオン及び治療方法
|
WO2014150512A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Cba Pharma, Inc. |
Method and products for treating diabetes
|
AU2014235215A1
(en)
|
2013-03-15 |
2015-10-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
CN105764916B
(zh)
|
2013-06-05 |
2021-05-18 |
博士医疗爱尔兰有限公司 |
鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
|
WO2015042495A2
(en)
*
|
2013-09-22 |
2015-03-26 |
Jiva Pharma, Inc. |
Metformin salts to treat type2 diabetes
|
CA2926685A1
(en)
|
2013-10-09 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
AU2014347668A1
(en)
|
2013-11-05 |
2016-05-19 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compounds for the treatment of diabetes and disease complications arising from same
|
EP3094328B1
(de)
|
2014-01-15 |
2020-08-19 |
Poxel SA |
Verfahren zur behandlung von neurologischen, stoffwechsel- und anderen erkrankungen mit enantiomerenreinem deuterium-angereicherten pioglitazon
|
EP3110449B1
(de)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medizinische verwendung eines dpp-4-inhibitors
|
KR101606547B1
(ko)
*
|
2014-06-02 |
2016-03-28 |
김동연 |
공항 탑승객 위치조회시스템
|
PE20170950A1
(es)
|
2014-10-24 |
2017-07-13 |
Bristol Myers Squibb Co |
Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos
|
WO2016071727A1
(en)
|
2014-11-04 |
2016-05-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
|
MA39929A
(fr)
|
2014-11-27 |
2016-06-01 |
Arven Ilac Sanayi Ve Ticaret As |
Comprimé multicouche comprenant de la metformine et du pioglitazone
|
MX2018014938A
(es)
|
2016-06-08 |
2019-05-16 |
Support Venture Gmbh |
Combinaciones farmaceuticas para el tratamiento del cancer.
|
CN109310697A
(zh)
|
2016-06-10 |
2019-02-05 |
勃林格殷格翰国际有限公司 |
利格列汀和二甲双胍的组合
|
MX2019001819A
(es)
|
2016-08-17 |
2019-06-13 |
Support Venture Gmbh |
Metodo para prevenir o tratar la perdida de la audicion.
|
TR201620309A2
(tr)
|
2016-12-30 |
2018-07-23 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
|
AU2018248578A1
(en)
|
2017-04-04 |
2019-10-17 |
Kinarus Ag |
Methods of preventing or treating ophthalmic diseases
|
WO2019154893A1
(en)
|
2018-02-08 |
2019-08-15 |
Strekin Ag |
Oral extended release pharmaceutical compositions for preventing or treating hearing loss
|
WO2019154895A1
(en)
|
2018-02-08 |
2019-08-15 |
Strekin Ag |
Gel formulation for preventing or treating hearing loss
|
US11273158B2
(en)
|
2018-03-05 |
2022-03-15 |
Alkermes Pharma Ireland Limited |
Aripiprazole dosing strategy
|
SG11202012775SA
(en)
|
2018-07-13 |
2021-02-25 |
Kinarus Ag |
Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
|
CN111875598B
(zh)
*
|
2020-05-23 |
2023-10-10 |
白银京宇新药业有限公司 |
一种吡格亚胺的制备方法
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
EP4196120A1
(de)
|
2020-08-11 |
2023-06-21 |
Kinarus AG |
Verfahren zur prävention oder behandlung von covid-19 und verwandten viruserkrankungen oder -störungen
|
IL301793A
(en)
|
2020-09-30 |
2023-05-01 |
Duality Biologics Suzhou Co Ltd |
Anticancer compound and method for its preparation and use
|